• Dr. Swanson most recently co-founder of publicly listed PolarityTE, a biotech company focused around developing regenerative tissue products, biomaterials
• Prior to PolarityTE, Dr. Swanson served as resident in plastic and reconstructive surgery at John Hopkins University School of Medicine
• Healthtech Solutions has adopted a unique portfolio business model, recently announcing acquisition of precision oncology company Varian Biopharmaceuticals

Healthtech Solutions (OTC: HLTT), the parent company of Varian Biopharmaceuticals Inc., Medi-Scan Inc. and RevHeart Inc., have recently announced the appointment of Edward Swanson, MD as the company’s new Chief Executive Officer (https://ibn.fm/444X7). The appointment, which is effective as of May 14, 2021, will see Dr. Swanson replace David Rubin as Healthtech Solutions’ CEO. “With Ned Swanson at the helm of Healthtech Solutions, we have the leadership and expertise of an individual who has demonstrated success at both medical bioengineering and effective public company stewardship at C-level,” said Healthtech Solutions Chairman David Rubin. “His direction will facilitate a rise to a new level for the company and serve to deliver continued growth and shareholder value.” Dr. Swanson has a long and distinguished background that makes him particularly well suited to lead Healthtech going forward, drawing from a broad array of scientific, clinical and industry specific experiences. Dr. Swanson is a co-founder of PolarityTE, Inc. (NASDAQ: PTE), a biotech company focused around developing a range of regenerative tissue products and biomaterials, led by its flagship product SkinTE(R). During his tenure at PolarityTE, Dr. Swanson was able to draw on a range of experiences in building and leading a publicly listed company, serving in a wide variety of roles, including director, chief operating officer, and chief medical officer. In addition to his positions at PolarityTE, Dr. Swanson also served as the CEO of PolarityTE’s subsidiaries, Utah CRO Services Inc. and IBEX Preclinical Research Inc., which specialized in offering preclinical contract research services. Prior to PolarityTE, Dr. Swanson was a resident in plastic and reconstructive surgery at The John Hopkins University School of Medicine. During his tenure at John Hopkins, Dr. Swanson published over 45 peer-reviewed papers, authored four book chapters, and delivered upwards of 30 conference presentations. Dr. Swanson is a graduate of the University of Pennsylvania’s School of Engineering and Applied Science and obtained his M.D. from Harvard Medical School. Healthtech Solutions has sought to adopt a unique, portfolio-style business model, with the company recently agreeing to purchase Varian Biopharmaceuticals Inc., a precision oncology company developing novel therapeutics for the treatment of cancer (https://ibn.fm/XP0L7). The acquisition will add to HLTT’s growing healthcare portfolio, which also features cloud-based ultrasound technology provider, Medi-Scan Inc., as well as RevHeart Inc., a wholly owned subsidiary focused around treating COVID-related heart muscle injury. “I am thrilled to be joining the Healthtech team to build out a unique portfolio-style business model to bring innovative biotech and medical device technologies to the market and impact patient lives,” said Dr. Swanson. “The decentralized development of assets in this structure leverages nimble operating efficiencies at the subsidiary level combined with the experience and skillsets of the management team of Healthtech.” For more information on, visit the company’s website at www.HealthTechSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

Live Streaming Event Date: 8,9, 10 June 2021 The LD Micro Invitational XI Virtual Event will be held in June, from 8th to 10th. Companies, shareholders, and investors of the small-cap trading community are invited to attend this influential conference that is addressed by some eminent industry stalwarts. The 3-day itinerary of the event is as follows:

• 8th June – Day 1 – Celebration of The LD Micro Hall of Fame that features the top 50 performing companies out of the 1500+ names that have presented
• 9th and 10th June – Day 2 & 3 – These days are allocated to companies for their 25- minute presentations. No Q&A sessions.

LD Micro was acquired in 2020 by SRAX (NASDAQ: SRAX) a data-powered technology company, that leverages the potential of its premier Saas platform, Sequire, for public traded companies to track their investors’ behavior, trends, and movement. Based on these reliable data sets gathered across several industry verticals, they engage current and potential investors across marketing channels. SRAX is a digital marketing company that focuses on precisely identifying target consumers for brands and companies in the CPG, investor relations, luxury, and lifestyle spaces and aiding them to unlock the potential of the gathered data. Sequire recently reached a milestone mark of 5 million retail investors. This is attributed to the tremendous benefits this platform offers mid-cap companies who can get real-time market data like current share price, value change, your level two data and so much more. Further, can also build an extensive profile of their target investors to engage them through marketing campaigns. To know more about the event, please visit https://ibn.fm/4nVzq

Date: June 8-11, 2021 Virtual Conference SMSS, a premier Social Media Conference is being held virtually from June 8-11^th, 2021. Companies, marketers, influencers, and social media enthusiasts are invited to attend this unique learning experience and connect directly with the stalwarts of social media marketing. The Influencer Marketing Strategies Summit is co-hosting this virtual event. Distinguished speakers from all over the globe of the social media influencer community will share keynotes, opinions and discuss updated topics that will help brands grow and reach out to the targeted audience. This 4-day event offers brands, marketers, and startups a wonderful opportunity to connect with social media personnel and learn the intricacies of a successful online campaign so that brands can get easily noticed by the audience. Further, brands will also learn strategies on how to earn the trust of their target audience, engage them and turn them into conversions. 40 Speakers from successful brands and business backgrounds will share their winning stories and inspire marketers to achieve their business goals. 6 Reasons to attend the SMSS Summit:

1. Learn the intricacies of designing a successful social media strategy
2. Connect with industry influencers and collect all resources to emerge a champion of social media marketing in your workplace
3. Analyze and improvise your existing social media strategies based on real-life experiences, feedback, and suggestions acquired at the summit
4. Witness a distinguished gathering of eminent industry leaders learn about their journey and seek inspiration
5. Understand the goals and strategies behind case studies and compare them with your brand strategies
6. Give your career a boost and emerge a leader in your social media marketing role by gathering valuable marketing insights at the conference

The event will commence with Welcome Remarks from Summit Emcee Joe Cox, Founder & Creator, The Pop-Marketer. SMSS is the top online event for senior-level marketing professionals who can avail this consolidated platform to hone their marketing skills and gain professional insights into new and emerging influencer marketing tools and strategies. Group discounts are also available. If you are looking to grow your business online, connect with this 4 days of content and networking summit. To know more about the details of the event, please visit https://ibn.fm/aVxVf

• Entertainment fintech firm BAND Royalty has created an NFT art offering that starts at only 1 Ethereum per NFT art piece. Each NFT art piece gives anyone holding it access to the secretive world of buying and selling music royalties. Using a new type of art NFT that is also a music NFT DeFi opportunity, BAND Royalty has developed a utility for its art NFTs that allows fans to connect to their favorite music artists and share in their income, through music royalties.
• The top 3 one of a kind NFTs in the BAND Royalty limited edition music NFT series, entitled “Every time it’s played”, secured more than $200,000 in Ethereum equivalence in a private presale, with the remainder of the music NFT artwork available for an exclusive sale directly on their website. With 15 curated images distributed over 8 different rarity levels this unique NFT series is the first of its kind to have a built in defi-component developed right into its purpose.
• The NFTs can be staked for revenue shared into various DeFi royalty pools tied to select song catalogs that have songs performed by artists such as Beyonce, Cher, Justin Timberlake, and Rihanna.
• BAND has debuted a one-of-a-kind music industry, the only NFT marketplace to trade their NFTs and eventually to open it up as a whole to the music industry. This is just a small part of the company’s ongoing growth and development plans.

Music industry revenue machine disruptor BAND Royalty is pairing DeFi innovation with digital Hi-Fi wizardry to democratize the way fans enjoy connecting with celebrities and the way performers own their brands. BAND Royalty’s non-fungible tokens (“NFTs”) appeal to the collectibles market, delivering distinctive 3D artwork for each limited-edition series. The NFTs will also be able to be staked, in order to gain access to a library of music royalties held by BAND, meaning that the NFTs can be contractually secured to BAND’s platform for a period of time to prevent their value trading elsewhere. In the model developed by BAND, this series of NFTs only contains 3,000 distinct art pieces, using 15 curated images celebrating music’s diversity of people and genres with a DeFi utility divided into eight different rarity levels. Anyone can get started with the largest rarity level having 1500 vinyl NFTs selling for only 1 ETH. Each one of the vinyl NFTs can be staked to one of BAND’s three royalty pools. So the more vinyl NFTs you own, the more staking spots you can carve out for yourself. The lowest numbered rarity in the series that BAND Royalty produced was the #1 one of a kind NFT art piece known as the “double diamond album”, worth 25 ETH or $100,000, which sold within 48 hours of the pre-sale announcement and is stake-able to all the royalty pools, with an additional BAND token being airdropped to owner once the company’s crypto ecosystem is launched in summer 2021. When staking starts, BAND’s NFTs will grant NFT holders access to a percentage of the music royalty revenue being generated by the extensive and diverse BAND Royalty music catalog. Each of the royalty types have been divided into three different music pools: publishing of printed music, public and mechanical performances of the music, and synchronization with visual media such as film, advertisements, or video games. BAND NFT stakers will participate in the revenue of songs performed by musicians such as Cher, Beyonce, will.i.am and Justin Timberlake, and various other performers as the catalog grows. Although the royalty staking does not transfer ownership of copyright or royalties possessed by the artist and by BAND, respectively, revenue from the royalty shares can give fans a feeling of owning a piece of their favorite artist’s success. The power of BAND’s vision was realized in the limited access private pre-sale of part of its first series, which netted 60 ETH for the top three albums — equivalent to more than $200,000 in Ethereum exchange at the time. The pre-sale brought in an overall total of more than $700,000 in Ethereum equivalence, according to the company’s news release (https://ibn.fm/ojFUW) in the various eight rarity levels. The public sale of the NFTs initially took place on Open Sea, the world’s largest NFT marketplace, but BAND has since created its own first-ever music-only NFT marketplace, which it operates through its website as the company continues to develop its vision of democratizing music royalty revenues. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

• Quarter growth, cash flow key metrics indicate company moving in the right direction
• Chalice reported record quarterly revenues from continuing operations of $5.5 million, increase in gross profit margin
• “Continued profitable operations and accretive acquisitions should set us up for a record-breaking second half of 2021,” says CEO

In a past Bloomberg video interview, Stonecastle Investment Management president Bruce Campbell commented on Golden Leaf Holdings (https://ibn.fm/g4jct), a premier consumer-driven cannabis company that earlier this month finalized a name change to Chalice Brands (CSE: CHAL) (OTCQB: GLDFF). In his comments, Campbell outlined what he felt needed to happen in order for the company to become a potential investment. “The new management team that’s taken over are good operators,” said Campbell, after noting the company’s previous erractic performance. “But what we need to see from them is probably see a couple of quarters of progress, and showing that they’re heading in the right direction. And we probably need them to sort of generate some cash flow, so that they don’t have to continue to raise money. “When we get that, I suspect the stock prices starts to move. But it’s probably going to be a little bit of a show-me story until they get to that point,” he continued, noting that the stock was one that Stonecastle has its eyes on. “We’ve met with the management team a couple of times, and they certainly know the business and understand the business; it’s a function of sort of right sizing everything.” The leadership team that Campbell referenced has focused on doing exactly that: right sizing the company so it becomes an option that, like Campbell, savvy investors take a close look at. This week, Chalice released its financial and operating results for Q1 2021, with numbers that reflect the progess Campbell outlined was necessary (https://ibn.fm/ioqJg). The company reported record quarterly revenues from continuing operations of $5.5 million, a 18% year-over-year increase compared to $4.7 million for the same period in 2020, and gross profit for the quarter of $2.5 million, or 45% gross margin compared to $1.7 million, or 37% gross margin in 2020. In addition, the report noted that adjusted EBITDA of approximately 7%, or $370,000, continues the trend from Q4 2020, demonstrating that Oregon covers corporate overhead costs. “Continued profitable operations and accretive acquisitions should set us up for a record-breaking second half of 2021,” said Chalice Brands CEO, Jeff Yapp. “We continue to look forward to favorable federal regulation changes while we grow Fifth & Root to showcase our brand portfolio nationally. Our team is energized and focused on growth as we remain disciplined in our allocation of capital.” Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The Company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. For more information, visit the company’s website at www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

• Recreational marijuana sales in Canada have been slow to take off despite legalization in October 2018 but look to be on the rise
• A survey carried out in February 2021 revealed that 40% of Canadian marijuana consumers still resorted to illegal means to obtain product due to poor quality of legal marijuana, lack of stock at retail outlets
• Pac Roots Cannabis seeks to avoid peers’ fate through relentless focus on premium-quality strains, coupled with strategic licensing agreement with Phenome One Corp
• Earlier this year, Canada’s legal market was shown to have finally overtaken illicit sales, commanding 56% of sector turnover

“The legal stuff is garbage”—so read a Reddit user’s comment on one of Vancouver’s cannabis-focused reddit feed earlier this year. Recreational marijuana was legalized across Canada in October of 2018 (https://ibn.fm/N5Mkj); however, since then, legal recreational marijuana sales have been slow to take off. Remarkably, a Canadian government survey released in February 2021 (https://ibn.fm/XS6Io) found that 40% of the country’s marijuana consumers admitted to having obtained the drug illegally since legalization – largely a result of the poor quality inherent to legal produce as well as a distinct lack of retail store locations. In the face of this, innovative cannabis up-and-comers are raising the quality bar. Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach, has sought to address the poor reputation of legal Canadian marijuana through a relentless focus on cutting-edge cultivation techniques. Pac Roots has entered into a strategic licensing agreement with Phenome One Corp, granting Pac Roots access to one of Canada’s largest live genetic cannabis libraries with lab and field-tested, selectively bred seedlings, which the company has employed to grow, breed and clone their own unique brands. The tie-up in turn has allowed Pac Roots to offer its customers a remarkable portfolio of over 350 meticulously designed cultivars, ranging from CBD-dominant plants with rare terpene profiles to plants with over 30% THC-content as well as West Coast outdoor, botrytis-resistant cultivars. “Preserving the excellence of our elite strains while introducing the highest quality of new strains to the public is our passion,” Pac Roots Cannabis states on its website. “Genetic variation and stability are the foundation that drives the decision making for our business” (https://ibn.fm/J2iuD). At least part of Phenome’s expertise lies in its state-of-the-art growing systems that are carefully designed to incorporate proprietary nutrient regimes with experience in all growing mediums. Phenome One’s elite line of rigorously tested production cultivars consists of hundreds of cultivars that have a minimum of nine commercial production cycles. Pac Roots has thus sought to avoid the fate of companies such as sector leader Canopy Growth (TSE: WEED), which has seen its market capitalization decline from over $24 billion in April 2019 to just over $8 billion at present (https://ibn.fm/JsVnx). In early 2020, Canopy Growth announced that it would be closing two cultivation greenhouses in British Columbia while simultaneously cancelling plans for a third greenhouse in Ontario. At the time, Canopy Growth’s management blamed the cutbacks on Canada’s recreational market, which they said had “developed slower than anticipated.” However, the Canadian recreational marijuana market may now be turning the corner. Earlier this year, data revealed that the legal market had finally overtaken illicit sales, accounting for 56% of sector turnover (https://ibn.fm/ccBZ4). Meanwhile, retail locations are now proliferating; about 50 locations a month are now opening in Ontario, leading prices to decline by approximately 20 percent since legalization due to the fierce competition among hundreds of licensed producers. With Canada’s legalized marijuana market finally on an upswing, Pac Roots Cannabis Corp.’s relentless focus on high-quality cultivars and marijuana products may place it in the ideal position to benefit from rising demand from an increasingly discerning Canadian retail consumer base. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Green Hygienics has launched TruLife Biotech LLC. to focus on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands
• The global industrial hemp market was valued at $5.66 billion in 2020 and is expected to reach a value of $27.72 billion by 2028, growing at a CAGR of 25.17%
• Hemp-derived cannabinoids have been studied for the last 20 years with nothing more than pre-clinical data but the new collaboration with Cinvestav and the creation of TruLife Biotech can help answer these questions and develop the products necessary for ECS deficiencies

Green Hygienics Holdings (OTCQB: GRYN), a California-based tech-driven enterprise focused on the high standard cultivation of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, recently announced that to advance R&D efforts, it has entered into a scientific research collaboration agreement with Cinvestav, the Center for Research and Advanced Studies of the National Polytechnic Institute of Mexico (Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional) (https://ibn.fm/8UnHo). Cinvestav is a high-ranked, leading Mexican multidisciplinary scientific research institute that will work with Green Hygienics in R&D efforts to develop cannabinoid-based products targeting the endocannabinoid system (“ECS”) deficiencies in animals and humans. Cinvestav ranks fourth among Latin American research centers and 118th worldwide. Green Hygienics is also launching TruLife Biotech, LLC. to advance studies in hemp-derived cannabinoid therapies, like the research conducted with Cinvestav. The focus of TruLife Biotech will be the development and advancement of innovative cannabinoid-based nutraceuticals, skincare products, and wellness brands addressing the ECS deficiencies in humans (https://ibn.fm/rCXOQ). “This research collaboration will be our first project under TruLife Biotech LLC, a Green Hygienics Company focused on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands,” Chief Scientific Officer Dr. Levan Darjania said. “The collaboration with Cinvestav will augment ongoing efforts by both parties to identify and explore selected cannabinoids and terpenes in planned combinations that may act synergistically to protect against pain development and determine their potential efficacy as pain relievers against inflammatory and neuropathic pain.” It is the collaborative model that Green Hygienics and Cinvestav will develop that will be used to create proprietary and effective products. “Discovery and development of cannabinoid-based products that are truly effective in producing the desired result are global tasks that are based on multidisciplinary approaches, collaborations, and partnerships. After meeting with leading researchers at Cinvestav’s Mexico City Campus, we are confident in our collaboration on the development of new and efficacious products,” COO Kyle MacKinnon added. Even though the interaction of hemp-derived cannabinoids and the body’s ECS has been studied for the last 20 years, there is only pre-clinical data available. Still, the question that arises is how much of that data is genuine and useful. The company intends to use the new collaboration and TruLife Biotech formation to help answer these questions and develop the products necessary for ECS deficiencies, according to Dr. Darjania. To further support the initiative, Green Hygienics has published a White Paper through Nutritional Outlook, an MJH Life Sciences(TM) brand that provides intelligent, well-informed insights and industry updates critical to the manufacturers of dietary supplements, health foods, and nutritional beverages. The White Paper examines the therapeutic potential for cannabinoid health- and wellness-based products, but underlines the need to develop defined, consistent, and targeted products with established standards. The ultimate goal is to develop and promote scientific evidence-based ECS-modulating cannabinoid products that will be trusted by medical communities, physicians, holistic health practitioners, and wellness-oriented end users (https://ibn.fm/9929I). According to Dr. Darjania, Green Hygienics remains committed to changing the landscape of the industry and continuing the advancement of its hemp-derived cannabinoid phyto-remedy platform, with TruLife serving as a hub of biotechnology innovations and ultimately securing a strategic advantage in the market by introducing novel cannabinoids and biodelivery methods. These steps will help cement Green Hygienics’ role in the global hemp market, which was valued at $5.66 billion worldwide in 2020. The market is expected to grow at a CAGR of 25.17% from 2021 to 2028, resulting in an estimated value of $27.72 billion by 2028 (https://ibn.fm/mZEGs) and multiple expansion opportunities for Green Hygienics and its portfolio. For more information, visit the company’s website at www.GreenHygienics.com. NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• ISWH is prepared for ups, downs of the Bitcoin sector and is set to make a profit regardless of the market’s erratic performance
• “Even with the recent correction, we will start monetizing our investment with a comfortable cushion of profitability on operations,” says ISWH CEO
• Pods owned, operated by ISW Holdings will be hashing at competitive rates

In a market renowned for a wild ride, ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in telehealth, renewable energy and cryptocurrency mining, announced that it is commencing hashing activities (https://ibn.fm/507oP). The company has been working in partnership with Bit5ive LLC (Bit5ive) to produce and begin operating proprietary POD5IVE mining pods at the Bit5ive cryptocurrency mining project based in Pennsylvania. ISWH is prepared for the ups and downs of the Bitcoin sector and is set to make a profit even with the erratic performance of the market. “We started down this road about a year ago, and it has been quite a remarkable journey to make it to this very exciting moment,” said ISW Holdings president and chair Alonzo Pierce. “Our analysis shows we can turn a clear profit with Bitcoin pricing above the low $20k’s. So, even with the recent correction, we will start monetizing our investment with a comfortable cushion of profitability on operations.” Pierce explained that the pods owned and operated by ISW Holdings will be hashing at competitive rates and that ISWH will also be participating in Bit5ive’s coordinated pooling strategy, which will include entering into the Bitmain mining pool. “We have strong tech, good partners, a high hash rate, an industry leading PUE, a zero carbon footprint target, and a pooled mining strategy that leverages top industry relationships established by our partner, Bit5ive,” Pierce states. ISWH and Bit5ive partnered last year, with a shared commitment to becoming leaders in the cryptocurrency mining space. “Like the gold rush of 1848, hordes of computer-savvy entrepreneurs have flocked to mining cryptocurrencies looking for riches,” noted an article featuring ISW Holdings and its involvement in crypto mining (https://ibn.fm/IyoA6). “Crypto miners extract the digital rewards of Bitcoin plus a share of transaction fees using purpose-built hardware, cost-effective power sources and computational muscle, the picks and shovels of the 21st century. The rewards appear to be greater than striking a motherlode—the global cryptocurrency mining market was valued at US $610 million in 2016 and has been projected to exceed $38 billion by 2025. Intent on capitalizing on the crypto mining market boom, ISW Holdings intends to deliver innovative crypto mining solutions by leveraging its new joint venture with Bit5ive.” The article noted that ISW Holdings is a holding company built of diversified partnerships focused on a common goal of brand communication from developers, consultants, design engineers, contractors, subcontractors, equipment providers, installation providers, end-users, and service providers. Bit5ive is a leader in cryptocurrency mining data centers with several projects currently in development in the United States. “The synergistic partnership of the two companies intends to capture a sizable share of the burgeoning crypto mining market,” the article states. ISWH’s partnership with Bit5ive points toward a common objective of driving ISWH’s crypto mining and renewable energy-portfolio enterprises to new levels of profitability. In addition to crypto mining and renewable energy, ISWH’s diverse portfolio includes home health care for the chronically ill, wellness and restoration, the adult beverage industry, and early-stage operations in supply chain and logistics management end users. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs
• Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications
• The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021
• Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and capital markets to draw on in developing its product
• The company is also working with pharmaceutical partners whose diversity of experience will provide support for Tryp’s path to oral psilocybin development

Bio-pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is working to develop novel solutions for diseases that otherwise have unmet medical needs, focusing its flagship initiative on fibromyalgia and binge eating conditions with a team of experienced professionals and skilled partners set to accelerate the development of its products. Tryp’s TRP-8802 synthetic psilocybin Active Pharmaceutical Ingredient (“API”) will soon be used to initiate Phase 2a clinical trials at the University of Florida for efficacy in treating specific neurologic causes of eating disorders — primarily hyperphagia, which is a condition in which the patients never feel full, so they are continually wanting to eat. Tryp’s trademarked Psilocybin-for-Neuropsychiatric Disorders (“PFN”)(TM) program is also focused on the chronic pain associated with fibromyalgia. The novelty of developing psychedelic substances for medicinal purposes requires that the program be led by individuals with significant drug development experience. Tryp’s team of executives and advisors made up of deep understanding gained through their work in large pharma, emerging pharma, drug approvals, psychedelics and capital markets, as noted in a recent NetworkNewsAudio broadcast (https://ibn.fm/P2SXq). The company’s executive team boasts decades working in leadership positions with Genzyme, Unigene Laboratories, Syntex, Nventa Biopharmaceuticals, Dow Chemical, ImmunoPrecise, Jubilant, and other organizations. Tryp’s COO, Tom D’Orazio, has helped shepherd two cancer drugs through the approval process with Health Canada, and the company’s Vice President, Manufacturing, Larry Norder, worked with early-stage research, preclinical and clinical developments for the blockbuster nonsteroidal anti-inflammatory drug Naproxen, the generic name for pain-reliever Aleve. Pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida is directing the investigation of Tryp’s TRP-8802 psilocybin product. As director of University of Florida Health’s Prader-Willi Syndrome (“PWS”) Program and professor in the Division of Pediatric Endocrinology at the University of Florida Department of Pediatrics, she follows one of the largest cohorts of PWS patients in the world. PWS is a genetic disorder involving chromosomal loss or alteration whose patients experience difficulties adapting to changes, uncontrolled mood, insatiable hunger — known clinically as hyperphagia — and food impulsivity. This frequently leads to the negative health effects associated with obesity, although researchers have noted that the lockdowns resulting from the COVID pandemic have led to significant weight loss in a large percentage of patients (https://ibn.fm/F3R2x). Pharmaceutical research companies are partnering with Tryp to provide support services for the development of its synthetic psilocybin product. Psychedelic therapy educational platform Fluence will provide design and training for the psychotherapeutic portion of Tryp’s upcoming clinical trials (https://ibn.fm/qxc92). Global novel pharmaceutical product contract research organization (“CRO”) Clinlogix will provide its support services for clinical trials (https://ibn.fm/8b5kY), and Tryp announced on May 25 that global pharmaceutical contract development and manufacturing organization Alcami Corporation will support development of proprietary oral formulations for TRP-8802, which is manufactured by Albany Molecular Research, Inc. (“AMRI”) (https://ibn.fm/TlTXi). Tryp expects to manufacture its initial batch of cGMP psilocybin API in September 2021, according to the company’s latest news release. Alcami and Tryp will then work together to develop the analytical methods and the final formulation for the oral psilocybin product. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million
• Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises
• Company subsidiaries reached several milestone achievements throughout the quarter.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, reported its financial results for first quarter 2021, the period ending March 31, 2021 (https://ibn.fm/kUVwH). The company also released key business updates along with its financial numbers. “The combination of equity transactions and retirement of our outstanding debt has brought significant value to our shareholders this quarter, as total stockholders’ equity increased by nearly $33 million,” said POAI Chief Executive Officer J. Melville Engle. “The Company’s subsidiaries continue to create value for our growing customer base as well.” POAI’s $35.5 million stockholders’ equity figure increased from the $2.6 million the company reported on Dec. 31, 2020. This included net proceeds of $35.6 million from a recent private placement, a registered direct offering and warrant exercises, as well as a balance of $27.3 million cash and cash equivalents. POAI’s balance sheet strengthened through the quarter as the company fully repaid outstanding debt incurred from 2018 to 2020. The company noted that its subsidiary Soluble Biotech had signed a contract with a pharmaceutical company to use Soluble Biotech’s proprietary protein formulation technology. Researchers from Helomics, another POAI subsidiary, also completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease, the report noted. “Soluble Biotech’s contract with this pharmaceutical company will allow the use of Soluble Biotech’s proprietary protein formulation technology in the improvement of the solubility and stability of a protein therapeutic destined for future clinical use. This may also lead to a strategic partnership for other therapeutics currently being developed by this pharma company,” reported Engle, who went on to note key highlights for the company’s other subsidiaries. “We are building a strong commercial pipeline for our unique Patient-cEntric Discovery by Active Learning (PeDAL)(TM), which we launched at the beginning of 2021. PeDAL brings together the key Helomics assets of real-world longitudinal data on 150,000 tumor drug response profiles and our clinically validated tumor assay with Quantitative Medicine’s active machine learning (‘AI’) technology. We believe the PeDAL platform will revolutionize early discovery and allow our pharma partners to significantly improve the chances that new drugs will translate into the clinic, saving costs and time,” said Engle, who also added that Helomics has initiated an internal drug repositioning project in ovarian cancer that the company believes will provide validation data to drive its commercial discussions and as potentially valuable intellectual property for licensing. Finally, TumorGenesis, another POAI subsidiary, is providing products that aid researchers at a top-tier laboratory to capture, culture and identify how ovarian cancer cells “break through” the protective lining in the abdomen—a valuable contribution in the understanding of how these cells migrate outside the abdominal cavity. “The results of this research could represent several billion dollars in future revenue for biotech and pharma companies, underscoring the value of TumorGenesis’s services and product lines to our customers,” Engle said. “We are pleased with the direction of the Company and how its subsidiaries are moving.  We are working towards leveraging our databases and intellectual property to fill the unmet market needs of pharmaceutical companies so they may deliver more targeted approaches to therapy, increasing our value to them while we all work together to improve patient outcomes,” he concluded. POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI